Melanoma Clinical Trial

Pilot Study of Imaging Human Skin With High-Speed Spectrally Encoded Confocal Microscopy

Summary

The aim of this study is to evaluate the imaging performance of Spectrally Encoded Confocal Microscopy (SECM) for imaging human skin and skin diseases.

View Full Description

Full Description

SECM provides an order of magnitude faster imaging speed than conventional confocal microscopy devices. The investigators have previously utilized the SECM technology for imaging large area of human esophagus in vivo. They have also developed endoscopic capsule devices which have been used to safely image over 60 human subjects, healthy volunteers and subjects with eosinophilic esophagitis, using SECM technology, rapidly.

When used for skin imaging, SECM can provide real-time three-dimensional confocal imaging and significantly reduce the imaging time. While SECM has been successfully used for imaging human esophagus in vivo, its utility in skin imaging needs to be tested in a new pilot study. The investigators will be taking images with a dermatoscope as well. This will the control to compare the experimental images to, as the dermatoscope is the standard of care diagnostic tool for dermatologists.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Healthy adults
18 years of age or older
Capable of giving informed consent
Pigmented lesions (such as moles) present on the forearm

Exclusion Criteria:

Unable to provide consent
Open cuts/sores on the skin, skin infection, or any contagious skin condition
Pregnant women (according to subject)
Employees under the direct supervision of the investigator

Study is for people with:

Melanoma

Estimated Enrollment:

10

Study ID:

NCT04566302

Recruitment Status:

Enrolling by invitation

Sponsor:

Massachusetts General Hospital

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Massachusetts General Hospital
Boston Massachusetts, 02114, United States

How clear is this clinincal trial information?

Study is for people with:

Melanoma

Estimated Enrollment:

10

Study ID:

NCT04566302

Recruitment Status:

Enrolling by invitation

Sponsor:


Massachusetts General Hospital

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.